https://orcid.org/0000-0002-6389-780X
Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Lili Sun, Zixiao Wang, Zhigang Yang, XiuJuan Liu & Haiyan Dong. (2023) Virtual screening and structure–activity relationship study of novel BTK inhibitors in Traditional Chinese Medicine for the treatment of rheumatoid arthritis. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-15.
Read now
Read now
Anna Wolska-Washer & Tadeusz Robak. (2022) Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Expert Review of Hematology 15:3, pages 183-194.
Read now
Read now
Articles from other publishers (10)
Peter C Taylor. (2023) Et tu, Brutinib? Demise of a kinase target in rheumatoid arthritis?. The Lancet Rheumatology 5:5, pages e241-e243.
Crossref
Crossref
Qian Ding, Wei Hu, Ran Wang, Qinyan Yang, Menglin Zhu, Meng Li, Jianghong Cai, Peter Rose, Jianchun Mao & Yi Zhun Zhu. (2023) Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Christian A. Fernandez. (2023) Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients. Current Opinion in Pharmacology 68, pages 102320.
Crossref
Crossref
Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sanchez‐Guerrero, Anand C. Patel, Dana Parsons‐Rich, Claire Le Bolay, Elise E. Drouin, Amy H. Kao, Hans Guehring & Maria Dall'Era. (2022)
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase
II
, Randomized,
Double‐Blind
,
Placebo‐Controlled Dose‐Ranging
Trial
. ACR Open Rheumatology 5:1, pages 38-48.
Crossref
Crossref
Huiming Tang, Hui Li, Yang Yang, Manli Tang, Zhanfei Li, Xiangjun Bai & Yuchang Wang. (2022) Ibrutinib protects against acute lung injury via inhibiting NLRP3/Caspase-1 in septic mice model. Molecular Immunology 152, pages 232-239.
Crossref
Crossref
Reda Ben Mrid, Najat Bouchmaa, Hassan Ainani, Rachid El Fatimy, Gabriel Malka & Loubna Mazini. (2022) Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis. Biomedicine & Pharmacotherapy 151, pages 113126.
Crossref
Crossref
Ewa Robak & Tadeusz Robak. (2022) Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. Journal of Clinical Medicine 11:10, pages 2807.
Crossref
Crossref
George Crișan, Nastasia Sanda Moldovean-Cioroianu, Diana-Gabriela Timaru, Gabriel Andrieș, Călin Căinap & Vasile Chiș. (2022) Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. International Journal of Molecular Sciences 23:9, pages 5023.
Crossref
Crossref
David J. Donnelly, Sean Preshlock, Tanpreet Kaur, Tritin Tran, Thomas C. Wilson, Karim Mhanna, Bradford D. Henderson, Daniel Batalla, Peter J. H. Scott & Xia Shao. (2022) Synthesis of Radiopharmaceuticals via “In-Loop” 11C-Carbonylation as Exemplified by the Radiolabeling of Inhibitors of Bruton's Tyrosine Kinase. Frontiers in Nuclear Medicine 1.
Crossref
Crossref
Sunhee Jang, Eui-Jong Kwon & Jennifer Jooha Lee. (2022) Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells. International Journal of Molecular Sciences 23:2, pages 905.
Crossref
Crossref